To review the optimal criteria and conditions for establishing a clinical registry, as well as detailing their application in a number of ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA) Registries already in existence.
INTRODUCTION
Strictly speaking, a patient or clinical Registry is defined as 'an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves (a) predetermined scientific, clinical, or policy purpose(s) [1]'. As such, the term 'Registry' can be applied to a variety of settings. This includes cross-sectional or longitudinally followed cohort studies, in which interventions are not being applied, particularly in which long-term follow-up is desirable. In contrast to case-control studies of treatment efficacy, registries are particularly to weigh the effect of potential confounders or treatment combinations or in situations in which placebo-controlled studies might either be unethical or blinding is impractical or in which randomization might be unethical or unnecessary. Registries can be applied effectively to studies of heterogeneous patient populations, because of the much broader inclusion criteria and fewer exclusion criteria that would otherwise be found in randomized clinical trials allowing surveillance for rare events or of rare diseases, or studies of standard of care, or healthcare access and barriers to care. In the last 10-15 years, a number of cohorts and registries of ankylosing spondylitis (AS) or axial spondyloarthritis (axSpA) patients have been established. This review will summarize the components of an optimally established Registry and illustrate these in currently available Registries and longitudinal cohorts.
Before date collection ensues, a group of individuals (an organizing committee) must come together to clearly establish the underlying purpose of the registry to be established (the endpoints), which investigators will constitute the leadership and oversight of the registry, who will be responsible for obtaining funding, and how the data will be collected, preferably by recruiting committed and trained investigators. This committee will also decide who will participate in the data collection and monitoring and which criteria will be used for patient recruitment and data entry, as well as inclusion/exclusion criteria, and mode of data collection and how they should be quantified (if at all). The latter is preferably done with standardized protocols (preferably those that have already been validated elsewhere) for which those contributing data to the study have received standardized training, in order to reduce interobserver variability. These rules are harder to apply in Registries with a large number of sites or clinicians contributing patients, in which standardized training is less feasible and other biases can creep in. Power issues relative to the endpoints being examined should be defined upfront and an appropriate sample size established. The endpoints and data points should also be realistic, collectable within the study budget and feasible in the setting of where the data will actually be extracted (clinics, insurance records, etc.). Issues surrounding retention in and adherence to the study should be addressed, and strategies to deal with the missing data planned upfront. The instruments should be subjected to pilot study to confirm their feasibility within the setting of the actual investigation. Coding manuals and data dictionaries should be employed to not only assure the data are collected uniformly, but also that they are entered and analyzed consistently and accurately.
CURRENT REGISTRIES IN SPONDYLOARTHRITIS
The Registries in spondyloarthritis (SpA) currently in existence generally are of two types. One is the medication-based or treatment-based registry, in which patients with multiple, often related diseases are enrolled to test the efficacy and side-effects of a given medication over time. These are often funded by drug companies or national governments, and are extremely useful in postmarketing surveillance. Examples of this are European Registries such as Base de Datos de Productos Bioló gicos de la Sociedad Española de Reumatología (BIOBADASER) [2] , Reuma.pt (The Rheumatic Diseases Portuguese Registry) [3] , NOR-DMARD. The Norwegian DMARD Registry [4] and South Swedish Arthritis Treatment Group Registry [5 & ] contain large numbers of SpA as well as other patients. On the other hand are diseasebased registries, either cross-sectional, in which a snapshot of the features of a disease in a large population is desired, or longitudinal, usually focused on endpoints defined at outset (disease progression, treatment efficacy or mortality). The latter will be the focus of this review.
Registro españ ol de espondiloartritis de la sociedad españ ola de reumatologia (Tables 1  and 2) This is a database registry initiated in April 2004 by the Spondyloarthritis Study Group of the Spanish Society of Rheumatology in order to establish a large enough cohort of patients to enable a representative determination of clinical disease features and disease progression, even from onset [6] . All hospital-based and community-based Rheumatology Units in Spain were invited to participate and maximum dissemination of information regarding the project is carried out among all Spanish. Clinical and demographic characteristics of the AS patients in this cohort are illustrated in Tables 1 and 2 [7] .
KEY POINTS
Registries are ideally organized systems using observational study methods to collect uniform clinical and other data to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, in order to serve predetermined scientific, clinical, or policy purpose(s).
Registries can be applied effectively to studies of heterogeneous patient populations, because of the much broader inclusion criteria and fewer exclusion criteria characteristic of randomized clinical trials allowing surveillance for rare events, studies of standard of care, healthcare access, and barriers to care.
What is key in establishing a Registry are clear goals established upfront, an oversight committee that establishes funding, policies and procedures and inclusion and exclusion criteria as well as a motivated and pretrained group of investigators using standardized and validated instruments to collect a realistic dataset.
A number of cohort studies and registries have been established in SpA over the last 15 years, especially in the last 5 years, which differ widely in their composition, often depending on their initial aims, referral patterns, and inclusion criteria.
Registro ibero-americano de espondiloartrites (Tables 1 and 2 JSpA, juvenile spondylarthritis; PsA, psoriatic arthritis; ReA, reactive arthritis; USpA, undifferentiated spondyloarthritis. Data from Gallinaro et al. [7] .
Ibero-American countries [6, 7] . The objective was to document demographic data, clinical data, and quality of life. Representative data from this cohort are shown in Tables 1 and 2 , in which very large clinical differences are seen between the 10 countries involved, perhaps reflecting differing referral patterns or clinical foci of the contributing sites.
Brazilian Registry of Spondyloarthritis (Table 2) This is a cross-sectional descriptive study developed at several tertiary healthcare centers in Brazil participating in the Brazilian Registry of Spondyloarthritis (BRS), which represents the five Brazilian geographic macroregions, with patients cared for from January 2006 to December 2009 [7] and including 1472 consecutive patients diagnosed with SpA. The diagnosis of SpA was considered when the patients met the modified New York criteria [8] .
Psoriatic arthritis (PsA) was considered when the patients met the Moll and Wright criteria [9] . The diagnosis of ReA was considered when asymmetric inflammatory oligoarthritis of the lower limbs was associated with enthesopathy and inflammatory low back pain after enteric and urogenital infections. Arthritis associated with inflammatory bowel disease (IBD) was considered in the presence of inflammatory axial pain and peripheral articular involvement associated with IBD (Crohn's disease or ulcerative colitis). Juvenile SpA was considered when the SpA symptoms began before the age of 16 years.
German Spondyloarthritis Inception Cohort (Table 3) This is an ongoing, prospective, longitudinal study on the clinical, functional, and structural outcome of SpA of short duration (inception cohort) [10] [8] , and the duration of symptoms was restricted to or less than 10 years at the time of inclusion. The classification of nonradiographic axial SpA was based on fulfillment of the European Spondyloarthropathy Study Group criteria [11] , with minor modifications, and the maximum duration of symptoms was or less than 5 years. Radiographs of the spine and sacroiliac joints were obtained at baseline and after 2 years. Data from this cohort are presented in Table 3 .
The Egyptian Spondyloarthritis Registry
This is a descriptive, multicenter, cross-sectional study including consecutive patients with SpA diagnosed according to the European spondyloarthritis study group criteria [11] The Spondyloarthritis Research Consortium of Canada Registry for spondyloarthritis (Table 4) This is a network of Canadian investigators interested in spondyloarthritis supported by The Arthritis Society [13] aimed at addressing the genetic basis of susceptibility of the disease and developing and validating clinical and imaging outcomes to assess disease activity and structural damage over time, the response to therapy, and the clinical burden of illness in terms of quality of life and disability. ] is a NIH funded study based at four academic medical centers in the United States followed longitudinally since 2002. As of January 2013, 961 patients had been enrolled (mean age 45 AE 14 years, 70.1% men, 81% white, 84.3% HLA-B27 positive, 32.2% with uveitis, 5.6% IBD, 11% psoriasis, and 45% on anti-TNF agents) of whom over 600 are still being longitudinally followed, with extensive standardized clinical, psychological, and sociodemographic instruments applied at each study visit, and genetic, serologic, and radiographic data collected and analyzed.
The Toronto University Health Network Spondylitis Program cohort (also participating in the SPARCC Registry), longitudinally followed on protocol since 2001, is a longitudinal observational cohort with prognostic, clinical, and translational research embedded [15] . Similar data have been collected as PSOAS cohort, and approximately 800 AS patients have been enrolled (mean age 41 AE 13 years, 76.4% men, 77.5% white, 80% HLA-B27 positive, 25.6% with uveitis, 13% IBD, 7% psoriasis, and 48% on anti-TNF agents).
PULSAR was initiated in 2007 to better characterize the clinical and pathophysiologic aspects of SpA in U.S. veterans. To date, 434 patients have been enrolled (mean age 59.1 years, 93% men, 72% white, 31% HLA-B27 positive, 23% AS, 35% PsA, 6% with uveitis, 3% IBD-associated SpA, 2% undifferentiated spondyloarthritis, and 42% on anti-TNF agents).
Outcome Assessments in Ankylosing Spondylitis International Study
This cohort is an international, longitudinal, observational historical cohort on outcomes in AS [16] comprised 217 consecutive Dutch, French, and Belgian patients with AS (of whom 85.3% were HLA-B27 positive) established in 1996 and followed into the next decade. All patients were TNF-Naïve, most having been treated primarily with NSAIDs alone and were felt to represent the spectrum of AS seen in practice at the time. The Outcome Assessments in Ankylosing Spondylitis International Study (OASIS) cohort was used as the comparison cohort for assessing the radiographic progression in most of the anti-TNF trials, including etanercept [17] , infliximab [18] , and adalimumab [19] .
Devenir dEs spondyloarthropathies ré centes
This large, national, multicenter, longitudinal, prospective follow-up of patients aged over 18 and less than 50 years from 25 regional centers in France presenting with early inflammatory back pain (IBP) was established by the French Society of Rheumatology in order to set up a database to facilitate several investigations on diagnosis, prognosis, epidemiology, pathogenesis, and medico-economics in the field of early IBP and SpA. Patients are being recruited if they have IBP of more than 3 months and less than 3 years, and are followed every 6 months during the first 2 years then every year during at least 5 years [20] . Data collected include demographics, disease activity, severity, comorbidities, socio-economics, treatments, radiological and MRI evaluation of the spine and the pelvis according to the local investigators. The recruitment period of the 708 patients (mean age: 34 AE 9 years, women 54%, HLA-B27 positive 57%) in the 25 centers was 26 months (from December 2007 to April 2010). The modified New York criteria, Amor criteria, ESSG criteria, and axial Assessment of SpondyloArthritis international Society (ASAS) criteria were fulfilled by 26, 77, 76, and 67% of the patients at entry, respectively. A history or current symptoms suggestive of peripheral arthritis, acute anterior uveitis, and inflammatory bowel disease were observed in 21, 9, and 4% of the patients, respectively.
Spondyloarthritis Caught Early cohort ( 
Assessment of Spondyloarthritis
International Society cohort (Table 6) The ASAS cohort was compiled for the validation of the new classification criteria for axSpA. Patients with chronic back pain of at least 3 months with onset less than 45 years and with a suspicion of SpA but without a definite diagnosis were included and Table 6 . Demographic and clinical features of AS patients in the OSKAR cohort assessed according to a fixed protocol by rheumatologists who are experts in the field of SpA [22] . Assessments included past or current SpA features, C-reactive protein, and HLA-B27 typing. Plain radiographs of the pelvis were taken in all patients. The local rheumatologist and radiologist assessed sacroiliitis on standard radiograph [8] and the presence or absence of typical signs of active inflammation on pelvic MRI.
The Observation Study of Korean Spondyloarthropathy Registry cohort (Table 6) This is an ongoing, longitudinal, observation study on the clinical, functional, and structural outcome of spondyloarthritis in Korea [23] supported by the Korean Ministry for Health, Welfare, and Family Affairs. It includes patients meeting the modified New York criteria for AS. Clinical data included age, sex, duration of disease, age at onset of AS symptoms, family history of AS, history of uveitis and iritis, peripheral arthritis, enthesitis, and HLA-B27 carrier status, as well as functional capacity (BASFI).
CONCLUSION
The Registry concept is an optimal method to study the manifestations, prevalence, or outcomes in large heterogeneous populations of a given disease or exposure. Optimally applied, registries use strictly defined goals, endpoints, and standardized, validated methodologies that can be realistically applied by a motivated and well trained group of investigators or observers. The numerous registries and cohort studies in AS and SpA in the recent years illustrate both the benefits of careful preplanning as well as some of the problems with local heterogeneity because of potential confounders. However, with the development of research technologies and treatments needing long-term studies of outcome and monitoring for rare complications beyond what is possible in a clinical trial or single cohort study, the need for such large-scale, longterm analyses that well designed and implemented Registries has never been greater.
